Opioid regulation of CNS dopaminergic pathways: A review of methodology, receptor types, regional variations and species differences

doi:10.1016/0196-9781(83)90003-7

Peptides

Volume 4, Issue 5, September–October 1983, Pages 595-601

https://doi.org/10.1016/0196-9781(83)90003-7 Get rights and content

Abstract

Biochemical measurements of DOPAC, HVA, DA and 3-MT allow the assessment of both DA metabolism in nerve endings and DA release into the synaptic cleft. Using these biochemical indices of DA neuronal activity, we have examined the actions of mu, delta and kappa opiate receptor agonists on the nigrostriatal pathway. These studies indicate that delta and mu₂ isoreceptors regulate activity in the nigrostriatal pathway of the rat, mouse, gerbil and hamster. In general, increased DA metabolism is observed; however, increased DA release is only evident in pathways devoid of a presynaptic clamping action. As indicated with enkephalinase inhibitors, these enkephalinergic inputs to dopaminergic neurons possess a phasic ongoing activity.

References (53)

L. Ahtee et al.
The effect of narcotic analgesics on the homovanillic acid content of rat nucleus caudatus
Eur J Pharmacol
(1973)
R. Collu et al.
Biochemical characterization of the dopaminergic innervation of the rat septum
Life Sci
(1980)
E. Costa et al.
An analysis at the synaptic level of the morphine action in striatum and N. accumbens: dopamine and acetylcholine interactions
Life Sci
(1975)
E.P. Finnerty et al.
Morphine suppression of substantia nigra zona reticulata neurons in the rat: Implicated role for a novel striatonigral feedback mechanism
Eur J Pharmacol
(1979)
C. Gauchy et al.
Acute effects of morphine on dopamine synthesis and release and tyrosine metabolism in the rat striatum
Eur J Pharmacol
(1973)
E.M. Joyce et al.
The effect of morphine applied locally to mesercephalic dopamine cell bodies on spontaneous motor activity in the rat
Neurosci Lett
(1979)
R.J. Katz et al.
Enkephalin -dopamine interactions in behavioral arousal
Prog Neuropsychopharmacol
(1979)
Y. Kondo et al.
Diminished responses of nigral dopaminergic neurons to haloperidol and morphine following lesions in the striatum
Brain Res
(1980)
K. Kuschinsky et al.
Effects of morphine on striatal dopamine metabolism: Possible mechanism of its opposite effect on locomotor activity in rats and mice
Eur J Pharmacol
(1974)
R.A. Lahti et al.
Properties of a selective kappa agonist, U-50,488H
Life Sci
(1982)

L.C. Murrin et al.

Striatal opiate receptors: pre- and postsynaptic localization

Life Sci

(1980)

R. Schulz et al.

Are there subtypes (isoreceptors) of multiple opiate receptors in the mouse vas deferens?

Eur J Pharmacol

(1981)

K. Spiegel et al.

Different receptors mediate morphine-induced prolactin and growth hormone release

Life Sci

(1982)

J.T. Williams et al.

Neurons in the frontal cortex of the rat carry multiple opiate receptors

Brain Res

(1981)

P.L. Wood et al.

Multiple opiate receptors: Differential binding of μ, κ and δ agonists

Neuropharmacology

(1981)

P.L. Wood

Multiple opiate receptors: Support for unique mu, delta and kappa sites

Neuropharmacology

(1982)

P.L. Wood

Phasic enkephalinergic modulation of nigrostriatal dopamine metabolism: Potentiation with enkephalinase inhibitors

Eur J Pharmacol

(1982)

P.L. Wood et al.

Morphine and nigrostriatal function in the rat and mouse: The role of nigral and striatal opiate receptors

Neuropharmacology

(1982)

P.L. Wood et al.

Striatal 3-methoxytyramine as an index of dopamine release: Effects of electrical stimulation

Neurosci Lett

(1982)

P.L. Wood et al.

Mu opiate isoreceptors: Differentiation with kappa agonists

Life Sci

(1982)

A.-Z. Zhang et al.

Nociception, enkephalin content and dipeptidyl carboxypeptidase activity in brain of mice treated with exopeptidase inhibitors

Neuropharmacology

(1982)

L.F. Agnati et al.

Aspects on receptor regulation and isoreceptor identification

Med Biol

(1980)

S. Algeri et al.

Effect of enkephalins on catecholamine metabolism in rat CNS

Adv Biochem Psychopharmacol

(1978)

G.F. Blane et al.

Dissociation of analgesic and respiratory depressant properties of N-substituted analogues of etorphine

J Pharm Pharmacol

(1968)

C.L.E. Broekkamp et al.

Stimulant effects of enkephalin microinjection into the dopaminergic A₁₀ area

Nature

(1979)

H.J. Broxterman et al.

HA-966 effects on striatal dopamine metabolism: Implications for dopamine compartmentalization

J Pharam Pharamcol

(1980)

Cited by (127)

Members of the same pharmacological family are not alike: Different opioids, different consequences, hope for the opioid crisis?
2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry
Citation Excerpt :
Although these interactions are important, particular focus should be drawn to the interaction of opioids with the D2 dopamine receptor system, drug specific differences in the nature and degree of this interaction, and the global consequences on mental health and addiction which these differential effects may have. The opioid and the dopaminergic systems are well established to interact with one another, with opioid drugs affecting the dopaminergic system and dopaminergic agonists and antagonists likewise affecting opioid drug effects (Bozarth and Wise, 1981; Nowycky et al., 1978; Volkow, 2010; Wood, 1983; Wood et al., 1980). This effect seems to critically involve the D2-like dopamine receptors (Capasso and Sorrentino, 1997; Kamei and Saitoh, 1996; Maldonado et al., 1997), a family that includes the representative D2 receptor (D2DR), as well as the more region-specific D3 and D4 receptors (Sibley and Monsma Jr., 1992).
Pain management is the specialized medical practice of modulating pain perception and thus easing the suffering and improving the life quality of individuals suffering from painful conditions. Since this requires the modulation of the activity of endogenous systems involved in pain perception, and given the large role that the opioidergic system plays in pain perception, opioids are currently the most effective pain treatment available and are likely to remain relevant for the foreseeable future. This contributes to the rise in opioid use, misuse, and overdose death, which is currently characterized by public health officials in the United States as an epidemic. Historically, the majority of preclinical rodent studies were focused on morphine. This has resulted in our understanding of opioids in general being highly biased by our knowledge of morphine specifically. However, recent in vitro studies suggest that direct extrapolation of research findings from morphine to other opioids is likely to be flawed. Notably, these studies suggest that different opioid analgesics (opioid agonists) engage different downstream signaling effects within the cell, despite binding to and activating the same receptors. This recognition implies that, in contrast to the historical status quo, different opioids cannot be made equivalent by merely dose adjustment. Notably, even at equianalgesic doses, different opioids could result in different beneficial and risk outcomes. In order to foster further translational research regarding drug-specific differences among opioids, here we review basic research elucidating differences among opioids in pharmacokinetics, pharmacodynamics, their capacity for second messenger pathway activation, and their interactions with the immune system and the dopamine D2 receptors.
Interaction between the dopaminergic and opioidergic systems in dorsal hippocampus in modulation of formalin-induced orofacial pain in rats
2014, Pharmacology Biochemistry and Behavior
Citation Excerpt :
Administration of morphine through the nucleus raphe magnus has an analgesic effect on orofacial pain (Duale et al., 2007). There is a fundamental overlap between opioidergic and dopaminergic effects (Nestler, 1996; Wood, 1983). Dopamine release could be facilitated in the nucleus accumbens (NAc) by the activity of opioidergic neurons in the VTA or NAc (Koob and Volkow, 2010).
The hippocampus is a region of the brain that serves several functions. The dopaminergic system acts through D1- and D2-like receptors to interfere in pain modulation and the opioid receptors play major roles in analgesic processes and there are obvious overlaps between these two systems. The present study investigated the interaction between the opioidergic and dopaminergic systems in the dorsal hippocampus (CA1) region for formalin-induced orofacial pain. Two guide cannulae were stereotaxically implanted in the CA1 region and morphine (0.5, 1, 2 and 4 μg/0.5 μl saline) and naloxone (0.3, 1 and 3 μg/0.5 μl saline) were used as the opioid receptor agonist and antagonist, respectively. SKF-38393 (1 μg/0.5 μl saline) was used as a D1-like receptor agonist, quinpirole (2 μg/0.5 μl saline) as a D2-like receptor agonist, SCH-23390 (0.5 μg/0.5 μl saline) as a D1-like receptor antagonist and sulpiride (3 μg/0.5 μl DMSO) as a D2-like receptor antagonist. To induce orofacial pain, 50 μl of 1% formalin was subcutaneously injected into the left side of the upper lip. Our results showed that different doses of morphine significantly reduced orofacial pain in both phases induced by formalin. Naloxone (1 and 3 μg) reversed morphine induced analgesia in CA1. SKF-38393 and quinpirole with naloxone (1 μg) significantly decreased formalin-induced orofacial pain in both phases. SCH-23390 had no effect on the antinociceptive response of morphine in both phases of orofacial pain. Sulpiride reversed the antinociceptive effects of morphine only in the first phase, but this result was not significant. Our findings suggest that there is cross-talk between the opioidergic and dopaminergic systems. Opioidergic neurons also exerted antinociceptive effects by modulation of the dopaminergic system in the CA1 region of the brain.
Synaptic upregulation and superadditive interaction of dopamine D2- and μ-opioid receptors after peripheral nerve injury
2014, Pain
Citation Excerpt :
Although the molecular basis for this change is unclear, opioidergic modulation of dopamine efflux in the dorsal horn can be considered as a potential mechanism. Consistent with this view is the fact that opioids can influence dopamine release in the CNS [71–73] and promote the release of endogenous MOR ligands (such as met-enkephalin) that are present in superficial laminae of the dorsal horn [50] and are known to be promoted by noxious stimulation [16,42]. This suggests that an important determinant of D2R-mediated modulation may be endogenous MOR activity, which becomes tonically active after SNL while showing negligible activity basally [15].
A sound strategy for improving the clinical efficacy of opioids involves exploiting positive interactions with drugs directed at other targets in pain pathways. The current study investigated the role of dopamine receptor D2 (D2R) in modulation of spinal dorsal horn excitability to noxious input, and interactions therein with μ-opioid receptor (MOR) in an animal model of neuropathic pain induced by spinal nerve ligation (SNL). C-fiber–evoked field potentials in the spinal dorsal horn were depressed concentration dependently by spinal superfusion with the D2R agonist quinpirole both in nerve-injured and sham-operated (control) rats. However, quinpirole-induced depression was significant at 10 μmol/L after SNL but only at 100 μmol/L in control rats. This quinpirole effect was completely abolished by MOR antagonist CTOP at subclinical concentration (1 μmol/L) in nerve-injured rats, but was unaltered in sham-operated rats. Nine days after SNL, D2R was upregulated to both presynaptic and postsynaptic locations in dorsal horn neurons, as revealed by double confocal immunofluorescence stainings for synaptophysin and PSD-95. In addition, D2R/MOR co-localization was increased after SNL. Co-administration of 1 μmol/L quinpirole, insufficient per se to alter evoked potentials, dramatically enhanced inhibition of evoked potentials by MOR agonist DAMGO, reducing the IC50 value of DAMGO by 2 orders of magnitude. The present data provide evidence of profound functional and subcellular changes in D2R-mediated modulation of noxious input after nerve injury, including positive interactions with spinal MOR. These results suggest D2R co-stimulation as a potential avenue to improve MOR analgesia in sustained pain states involving peripheral nerve injury.
Differential effects of morphine and naltrexone on the in vitro LH secretion from male and female carp pituitary gland
2005, Comparative Biochemistry and Physiology - C Toxicology and Pharmacology
Citation Excerpt :
to GnRH and dopamine — the two main factors (stimulatory and inhibitory, respectively) controlling LH secretion in fish. Generally, in mammals opioids regulate physiological processes acting through the different receptor types: μ, κ, σ, δ, ɛ, ζ (Wood, 1983; Teiwani, 1996; Wu et al., 1998). Gonadotropin secretion is controlled mainly by μ or δ receptor type (Thom et al., 1996; Smith and Gallo, 1997; Bondanelli et al., 1998; Lieberman et al., 1998).
The in vitro effects of morphine (10^− 10, 10^− 8, 10^− 6 or 10^− 5 M) or/and naltrexone (10^− 6 or 10^− 8 M) on LH release from male and female carp (Cyprinus carpio L.) dispersed pituitary cells (obtained from fish at the time of late gonad recrudescence) were investigated. Morphine alone at the lowest tested concentration (10^− 10 M) increased LH secretion from the cells of males. On the contrary, in female cell incubations the highest concentrations of morphine (10^− 6 or 10^− 5 M) significantly lowered LH levels. Naltrexone alone (at both tested concentrations) had no influence on LH secretion, neither in males nor in females. However in the incubations of female cells it antagonised the influence of morphine at 10^− 10 or 10^− 8 M. In male cell incubations naltrexone abolished the stimulatory action of morphine at 10^− 10 M. The results suggest that in the in vitro culture of carp pituitary cells LH secretion is modulated by the opioids which affect the release of this gonadotropin through the typical opioid receptors and that the μ type of these receptors is involved in this process. The effects of opioid agonist and antagonist depend on the stage of gonadal maturity and the sex of fish i.e. the actual level of sex steroids.
Genetic and pharmacological manipulation of μ opioid receptors in mice reveals a differential effect on behavioral sensitization to cocaine
2004, Neuroscience
Cocaine-induced behavioral sensitization is a complex phenomenon involving a number of neuromodulator and neurotransmitter systems. To specifically investigate the role of the μ opioid receptor (MOR) in cocaine-induced behavioral sensitization in mice, both genetic and pharmacological approaches were undertaken. MOR-1 deficient mice of varying backgrounds (C57BL/6J, 129S6, F1 hybrid 129S6×C57BL/6J and 129S6×C57BL/6J) and wild-type C57BL/6J mice exposed continuously to naltrexone, an opioid receptor antagonist, received single daily injections of saline or cocaine for 10 days. All mice received a single cocaine challenge 7 days following the last saline or cocaine injection to test for the expression of sensitization. The locomotor-stimulating and sensitizing effects of cocaine observed in MOR-1 wild-type mice were absent in MOR-1 knockout mice maintained on the mixed 129S6×C57BL/6J background. In contrast, MOR-1 deficient mice developed on a C57BL/6J background showed an accentuated sensitivity to cocaine-induced locomotion. Cocaine's psychomotor activating effects were more pronounced in the MOR-1 C57BL/6J knockouts injected daily with cocaine than in the MOR-1 wild-type mice. Similar locomotor-stimulating and sensitizing effects were found in both F1 hybrid 129S6×C57BL/6J MOR-1 wild-type and MOR-1 knockout mice, while the 129S6 strain showed an overall indifference to cocaine. That is, both the locomotor-stimulating and sensitizing effects of cocaine were absent in both MOR-1 wild-type and MOR-1 knockout mice maintained on the 129S6 background. Lastly, the locomotor-stimulating and sensitizing effects of cocaine were attenuated in C57BL/6J wild-type mice exposed continuously to naltrexone. Collectively, these data support a role for opioidergic involvement in cocaine-influenced behavior in mice. Moreover, MORs appear to differentially modulate a sensitized response to cocaine in different strains of mice as delineated by MOR-1 gene deletion and pharmacological antagonism.
Reward deficiency syndrome: Genetic aspects of behavioral disorders
2000, Progress in Brain Research
The dopaminergic and opiodergic reward pathways of the brain are critical for survival since they provide the pleasure drives for eating, love and reproduction; these are called ‘natural rewards’ and involve the release of dopamine in the nucleus accumbens and frontal lobes. However, the same release of dopamine and production of sensations of pleasure can be produced by ‘unnatural rewards’ such as alcohol, cocaine, methamphetamine, heroin, nicotine, marijuana, and other drugs, and by compuslive activities such as gambling, eating, and sex, and by risk taking behaviors. Since only a minority of individuals become addicted to these compounds or behaviors, it is reasonable to ask what factors distinguish those who do become addicted from those who do not. It has usually been assumed that these behaviors are entirely voluntary and that environmental factors play the major role; however, since all of these behaviors have a significant genetic component, the presence of one or more variant genes presumably act as risk factors for these behaviors. Since the primary neurotransmitter of the reward pathway is dopamine, genes for dopamine synthesis, degradation, receptors, and transporters are reasonable candidates.

View all citing articles on Scopus

View full text

Opioid regulation of CNS dopaminergic pathways: A review of methodology, receptor types, regional variations and species differences

Abstract

Eur J Pharmacol

Life Sci

Life Sci

Eur J Pharmacol

Eur J Pharmacol

Neurosci Lett

Prog Neuropsychopharmacol

Brain Res

Eur J Pharmacol

Life Sci

Life Sci

Eur J Pharmacol

Life Sci

Brain Res

Neuropharmacology

Neuropharmacology

Eur J Pharmacol

Neuropharmacology

Neurosci Lett

Life Sci

Neuropharmacology

Aspects on receptor regulation and isoreceptor identification

Med Biol

Effect of enkephalins on catecholamine metabolism in rat CNS

Adv Biochem Psychopharmacol

Dissociation of analgesic and respiratory depressant properties of N-substituted analogues of etorphine

J Pharm Pharmacol

Stimulant effects of enkephalin microinjection into the dopaminergic A10 area

Nature

HA-966 effects on striatal dopamine metabolism: Implications for dopamine compartmentalization

J Pharam Pharamcol

Stimulant effects of enkephalin microinjection into the dopaminergic A₁₀ area